Free Trial
NASDAQ:MNKD

MannKind (MNKD) Stock Price, News & Analysis

MannKind logo
$3.60 -0.02 (-0.41%)
Closing price 07/3/2025 03:48 PM Eastern
Extended Trading
$3.61 +0.00 (+0.14%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MannKind Stock (NASDAQ:MNKD)

Key Stats

Today's Range
$3.55
$3.69
50-Day Range
$3.58
$5.04
52-Week Range
$3.52
$7.63
Volume
1.74 million shs
Average Volume
2.43 million shs
Market Capitalization
$1.10 billion
P/E Ratio
36.05
Dividend Yield
N/A
Price Target
$10.33
Consensus Rating
Buy

Company Overview

MannKind Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

MNKD MarketRank™: 

MannKind scored higher than 56% of companies evaluated by MarketBeat, and ranked 1375th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MannKind has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MannKind has only been the subject of 1 research reports in the past 90 days.

  • Read more about MannKind's stock forecast and price target.
  • Earnings Growth

    Earnings for MannKind are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MannKind is 36.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.55.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MannKind is 36.05, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.50.

  • Read more about MannKind's valuation and earnings.
  • Percentage of Shares Shorted

    8.23% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MannKind has recently decreased by 2.30%, indicating that investor sentiment is improving.
  • Dividend Yield

    MannKind does not currently pay a dividend.

  • Dividend Growth

    MannKind does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.23% of the float of MannKind has been sold short.
  • Short Interest Ratio / Days to Cover

    MannKind has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MannKind has recently decreased by 2.30%, indicating that investor sentiment is improving.
  • News Sentiment

    MannKind has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for MannKind this week, compared to 5 articles on an average week.
  • Search Interest

    8 people have searched for MNKD on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $846,298.00 in company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of MannKind is held by insiders.

  • Percentage Held by Institutions

    49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MannKind's insider trading history.
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

MannKind (NASDAQ:MNKD) Rating Lowered to Hold at Wall Street Zen
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

MNKD Stock Analysis - Frequently Asked Questions

MannKind's stock was trading at $6.43 at the start of the year. Since then, MNKD stock has decreased by 43.9% and is now trading at $3.6050.

MannKind Corporation (NASDAQ:MNKD) released its earnings results on Thursday, May, 8th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. The company's revenue was up 18.1% compared to the same quarter last year.
Read the conference call transcript
.

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Cos (BHC), Intel (INTC) and Netflix (NFLX).

Company Calendar

Last Earnings
5/08/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNKD
Employees
400
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$10.33
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+186.6%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
36.05
Forward P/E Ratio
36.05
P/E Growth
N/A
Net Income
$27.59 million
Pretax Margin
11.17%

Debt

Sales & Book Value

Annual Sales
$285.50 million
Cash Flow
$0.14 per share
Price / Cash Flow
26.08
Book Value
($0.29) per share
Price / Book
-12.43

Miscellaneous

Free Float
295,727,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
0.96

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:MNKD) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners